Elevated resting and exercise-induced cortisol levels after mineralocorticoid receptor blockade with canrenoate in healthy humans

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 10, 2004, Pages 5048-5052

  Wellhoener, Peter ^a   Born, Jan ^a   Fehm, Horst L ^a   Dodt, Christoph ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANRENOIC ACID; CORTICOTROPIN; HUMAN GROWTH HORMONE; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; PLACEBO;

ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED STUDY; EXERCISE; FEEDBACK SYSTEM; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS SYSTEM; NORMAL HUMAN; PHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZATION; REGULATORY MECHANISM; STIMULATION;

ADRENOCORTICOTROPIC HORMONE; ADULT; ALDOSTERONE ANTAGONISTS; CANRENOATE POTASSIUM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EXERCISE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; PITUITARY-ADRENAL SYSTEM; RECEPTORS, MINERALOCORTICOID; REST;

ANIMALIA;

EID: 6344288979     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-0086     Document Type: Article

References (41)

1. Funder JW 1994 Corticosteroid receptors and the central nervous system. J Steroid Biochem Mol Biol 49:381-384
2. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M 1998 Brain corticosteroid receptor balance in health and disease. Endocr Rev 19:269-301
3. Oitzl MS, De Kloet ER 1992 Selective corticosteroid antagonists modulate specific aspects of spatial orientation learning. Behav Neurosci 106:62-71
4. Holsboer F, Lauer CJ, Schreiber W, Krieg JC 1995 Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 62:340-347
5. Dodt C, Keyser B, Molle M, Fehm HL, Elam M 2000 Acute suppression of muscle sympathetic nerve activity by hydrocortisone in humans. Hypertension 35:758-763
6. Sudhir K, Jennings GL, Esler MD, Korner PI, Blombery PA, Lambert GW, Scoggins B, Whitworth JA 1989 Hydrocortisone-induced hypertension in humans: pressor responsiveness and sympathetic function. Hypertension 13: 416-421
7. Arvat E, Maccagno B, Giordano R, Pellegrino M, Broglio F, Gianotti L, Maccario M, Camanni F, Ghigo E 2001 Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans. J Clin Endocrinol Metab 86:3176-3181
8. Grottoli S, Giordano R, Maccagno B, Pellegrino M, Ghigo E, Arvat E 2002 The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. J Clin Endocrinol Metab 87:4616-4620
9. Ratka A, Sutanto W, Bloemers M, De Kloet ER 1989 On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocrinology 50:117-123
10. Funder JW, Feldman D, Highland E, Edelman IS 1974 Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors. Biochem Pharmacol 23:1493-1501
11. Rothuizen J, Reul JM, van Sluijs FJ, Mol JA, Rijnberk A, De Kloet ER 1993 Increased neuroendocrine reactivity and decreased brain mineralocorticoid receptor-binding capacity in aged dogs. Endocrinology 132:161-168
12. Krause W, Karras J, Seifert W 1983 Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man. Eur J Clin Pharmacol 25:449-453
13. Dodt C, Kern W, Fehm HL, Born J 1993 Antimineralocorticoid canrenoate enhances secretory activity of the hypothalamus-pituitary-adrenocortical (HPA) axis in humans. Neuroendocrinology 58:570-574
14. Born J, Steinbach D, Dodt C, Fehm HL 1997 Blocking of central nervous mineralocorticoid receptors counteracts inhibition of pituitary-adrenal activity in human sleep. J Clin Endocrinol Metab 82:1106-1110
15. Deuster PA, Chrousos GP, Luger A, DeBolt JE, Bernier LL, Trostmann UH, Kyle SB, Montgomery LC, Loriaux DL 1989 Hormonal and metabolic responses of untrained, moderately trained, and highly trained men to three exercise intensities. Metabolism 38:141-148
16. Petrides JS, Mueller GP, Kalogeras KT, Chrousos GP, Gold PW, Deuster PA 1994 Exercise-induced activation of the hypothalamic-pituitary-adrenal axis: marked differences in the sensitivity to glucocorticoid suppression. J Clin Endocrinol Metab 79:377-383
17. Petrides JS, Gold PW, Mueller GP, Singh A, Stratakis C, Chrousos GP, Deuster PA 1997 Marked differences in functioning of the hypothalamic-pituitary- adrenal axis between groups of men. J Appl Physiol 82:1979-1988
18. Singh A, Petrides JS, Gold PW, Chrousos GP, Deuster PA 1999 Differential hypothalamic-pituitary-adrenal axis reactivity to psychological and physical stress. J Clin Endocrinol Metab 84:1944-1948
19. Lee MH, Kim H, Lim BV, Chang HK, Lee TH, Jang MH, Shin MC, Lee J, Shin MS, Kim CJ 2003 Naloxone potentiates treadmill running-induced increase in c-Fos expression in rat hippocampus. Life Sci 73:3139-3147
20. Lee TH, Jang MH, Shin MC, Lim BV, Kim YP, Kim H, Choi HH, Lee KS, Kim EH, Kim CJ 2003 Dependence of rat hippocampal c-Fos expression on intensity and duration of exercise. Life Sci 72:1421-1436
21. Herman JP, Schafer MK, Young EA, Thompson R, Douglass J, Akil H, Watson SJ 1989 Evidence for hippocampal regulation of neuroendocrine neurons of the hypothalamo-pituitary-adrenocortical axis. J Neurosci 9:3072-3082
22. De Kloet ER 1991 Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol 12:95-164
23. Funder JW 1996 Mineralocorticoid receptors in the central nervous system. J Steroid Biochem Mol Biol 56:179-183
24. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H 1998 The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. J Clin Endocrinol Metab 83:3339-3345
25. Fletcher GF, Balady GJ, Amsterdam EA, Chaitman B, Eckel R, Fleg J, Froelicher VF, Leon AS, Pina IL, Rodney R, Simons-Morton DA, Williams MA, Bazzarre T 2001 Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation 104:1694-1740
26. Froelicher VF 1987 Exercise and the heart: clinical concepts. Chicago: Yearbook Medical Publishers Inc.
27. Dodt C, Hansen K, Uthgenannt D, Born J, Fehm HL 1994 Cholinergic potentiation of the meal-related rise in ACTH and cortisol concentrations in men. Exp Clin Endocrinol 102:460-466
28. Breier A 1989 A.E. Bennett Award Paper. Experimental approaches to human stress research: assessment of neurobiological mechanisms of stress in volunteers and psychiatric patients. Biol Psychiatry 26:438-462
29. Fehm HL, Voigt KH, Kummer G, Lang R, Pfeiffer EF 1979 Differential and integral corticosteroid feedback effects on ACTH secretion in hypoadrenocorticism. J Clin Invest 63:247-253
30. Bornstein SR, Chrousos GP 1999 Clinical review 104: adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs. J Clin Endocrinol Metab 84:1729-1736
31. Ehrhart-Bornstein M, Bornstein SR, Gonzalez-Hernandez J, Holst JJ, Waterman MR, Scherbaum WA 1995 Sympathoadrenal regulation of adrenocortical steroidogenesis. Endocr Res 21:13-24
32. Edwards AV 1998 Regulation of adrenal function in the conscious calf. Horm Metab Res 30:303-310
33. The RALES study group 1996 Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 78:902-907
34. Ceremuzynski L, Budaj A, Michorowski B 1983 Single-dose i.v. aldactone for congestive heart failure: a preliminary observation. Int J Clin Pharmacol Ther Toxicol 21:417-421
35. Abshagen U, Sporl S, L'Age M 1978 Non-interaction of spironolactone medication and cortisol metabolism in man. Klin Wochenschr 56:135-138
36. Deuster PA, Petrides JS, Singh A, Chrousos GP, Poth M 2000 Endocrine response to high-intensity exercise: dose-dependent effects of dexamethasone. J Clin Endocrinol Metab 85:1066-1073
37. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717
38. Bjorntorp P, Rosmond R 2000 Obesity and cortisol. Nutrition 16:924-936
39. Korte SM, Korte-Bouws GA, Koob GF, De Kloet ER, Bohus B 1996 Mineralocorticoid and glucocorticoid receptor antagonists in animal models of anxiety. Pharmacol Biochem Behav 54:261-267
40. Rosmond R, Bjorntorp P 1998 Endocrine and metabolic aberrations in men with abdominal obesity in relation to anxio-depressive infirmity. Metabolism 47:1187-1193
41. Yau JL, Noble J, Seckl JR 1999 Continuous blockade of brain mineralocorticoid receptors impairs spatial learning in rats. Neurosci Lett 277:45-48